Clinical Trial Results - Progress in Cancer Care
These summaries highlight recently released results from cancer clinical trials. The findings are significant enough that they are likely to influence your medical care.
The summaries are listed in reverse chronological order. You may also use the navigation tools on the left to search the summaries by keyword or type of cancer.
- Crizotinib Improves Progression-Free Survival in Some Patients with Advanced Lung Cancer (Updated)
(Updated: 10/06/2014) - Results from an international phase III trial show that crizotinib (Xalkori®) substantially extends progression-free survival in previously treated patients with advanced lung cancer whose tumors have a specific genetic mutation.
- Rituximab Retreatment after Disease Progression Is Comparable to Rituximab Maintenance Therapy in Patients with Low-Tumor Burden Follicular Lymphoma
(Posted: 10/02/2014) - In a randomized clinical trial, patients with low–tumor burden follicular lymphoma whose cancer responded to initial treatment with rituximab (Rituxan®) experienced similar disease control regardless of whether they subsequently received maintenance therapy with rituximab or were retreated with rituximab only when there was evidence of disease progression.
- Two Drugs that Hit One Target Improve Survival in Women with Metastatic Breast Cancer
(Updated: 10/01/2014) - Combining two drugs that target the HER2 protein, trastuzumab (Herceptin®) and pertuzumab, with chemotherapy is a new treatment option for women with HER2-positive metastatic breast cancer, according to final results from a large clinical trial.
- Enzalutamide Improves Survival in Patients with Metastatic Prostate Cancer
(Posted: 06/27/2014) - In an international randomized phase III clinical trial, the hormone therapy enzalutamide (Xtandi®) extended survival in men with metastatic prostate cancer that had progressed during treatment with androgen deprivation therapy. Participants in the trial had not received chemotherapy.
- Ibrutinib Improves Survival Compared with Ofatumumab in Patients with Previously Treated Chronic Lymphocytic Leukemia
(Posted: 06/27/2014) - In an international randomized phase III clinical trial, patients with relapsed or refractory chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) who were treated with ibrutinib (Imbruvica®) lived longer without their disease getting worse than patients who received ofatumumab (Arzerra®). Patients who received ibrutinib also lived longer and were more likely to show a clinical response to treatment than those who received ofatumumab.